Source comparison
TB-500 Biomarkers: Clinical Reference Ranges Versus Research Context
Standard clinical labs report IGF-1 in nanograms per milliliter (ng/mL) with reference ranges varying by age and sex. Typically 100–300 ng/mL for adults aged 25–45. TB-500 administration doesn't push IGF-1 into supraphysiological ranges the way exogenous growt
This comparison does not assign a generated winner or score.
- Standard clinical labs report IGF-1 in nanograms per milliliter (ng/mL) with reference ranges varying by age and sex. Typically 100–300 ng/mL for adults aged 25–45. TB-500 administration doesn't push IGF-1 into supraphysiological ranges the way exogenous growth hormone does; instead, it shifts values toward the upper quartile of normal or slightly above (320–380 ng/mL). This makes TB-500 biomarkers difficult to flag as abnormal in isolation. A value of 340 ng/mL could reflect TB-500 use, natural variation, or recent high-intensity training.
- VEGF presents a similar challenge. Serum VEGF ranges from 50–500 picograms per milliliter (pg/mL) in healthy adults, with significant day-to-day variability driven by hypoxia exposure, inflammation, and meal timing. TB-500 typically elevates VEGF to 450–650 pg/mL during the 48–96 hour post-administration window. High-normal to mildly elevated, not diagnostic on its own. CRP follows the same pattern: normal values sit below 3.0 mg/L, TB-500 consistently suppresses CRP into the 0.8–1.5 mg/L range, but that range overlaps with outcomes from weight loss, anti-inflammatory diets, or statin therapy.
- Our experience reviewing peptide research protocols shows that TB-500 biomarkers gain diagnostic value through pattern recognition and serial measurement. A baseline IGF-1 of 180 ng/mL that jumps to 340 ng/mL within 72 hours, accompanied by VEGF rising from 200 pg/mL to 580 pg/mL and CRP dropping from 2.8 mg/L to 1.2 mg/L, creates a biomarker signature that non-peptide interventions rarely replicate. Timing matters. Labs drawn at 48–72 hours post-administration capture peak expression, while labs drawn at 10–14 days show inflammatory suppression but miss the acute angiogenic response.